ADPT
Adaptive·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ADPT
Adaptive Biotechnologies Corporation
A commercial stage biotech company that translates the genetics of the adaptive immune system into clinical products to diagnose and treat disease
Life Science Tools and Services
09/08/2009
06/27/2019
NASDAQ Stock Exchange
619
12-31
Common stock
1165 Eastlake Avenue East, Seattle, Washington 98109
--
Adaptive Biotechnologies Corporation was incorporated in Washington State on September 8, 2009. The company is advancing the field of immune-driven medicine by leveraging the inherent biology of the adaptive immune system to transform the diagnosis and treatment of diseases. The company believes that the adaptive immune system is nature's most sophisticated diagnosis and treatment for most diseases, but the inability to decode it prevents the medical community from taking full advantage of its capabilities. The company's immunomedicine platform applies proprietary technology to read multiple genetic codes of a patient's immune system and understand exactly how to detect and treat that patient's disease. The company's immunomedicine platform applies proprietary technology to read multiple genetic codes of a patient's immune system and understand exactly how to detect and treat that patient's disease. The company captures these insights in the Dynamic Clinical Immunomics Database, which is based on computational biology and machine learning for the development and commercialization of clinical products and services that companies are tailoring to each patient.
Earnings Call
Q1/2025
Estimate EPS-0.31
Actual EPS-0.2
Estimate Revenue42.13M
Actual Revenue52.44M
Adaptive Biotechnologies Q1 2025: Unpacking Contradictions in EMR Integration, ASP Growth, and Pharma Trial Strategies
May 02,2025 07:32
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ADPT has released its 2025 Q3 earnings. EPS was reported at 0.06, versus the expected -0.14, beating expectations. The chart below visualizes how ADPT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ADPT has released its 2025 Q3 earnings report, with revenue of 93.97M, reflecting a YoY change of 102.38%, and net profit of 9.54M, showing a YoY change of 129.74%. The Sankey diagram below clearly presents ADPT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
